The purpose of this prospective clinical data-collection is to document the performance and clinical outcomes of the Balance® Microplasty™ Hip System...
Date First Received: June 13, 2008
Last Updated: July 3, 2008
Verified by: Biomet, Inc., July 2008
Clinical Trial Phase: N/A | Start Date: January 2005
Overall Status: Active, not recruiting
Estimated Enrollment: 100
Brief Summary
Official Title: “A Prospective, Non-Controlled, Clinical Investigation of the Balance® Microplasty™ Hip System”
Condition Keyword(s):
The purpose of this prospective clinical data-collection is to document the performance and clinical outcomes of the Balance® Microplasty™ Hip System.
Study Type: Observational
Study Design: Cohort, Prospective
Study Primary Completion Date: December 2013
Arms, Groups and Cohorts in this Clinical Trial
- : Balance® Microplasty™ Hip System
Outcome Measures for this Clinical Trial
Primary Measures
- Harris Hip Score
- Time Frame: 6 weeks, 6 months, 1 year, 3 years, 5 years
Safety Issue?: No
- Time Frame: 6 weeks, 6 months, 1 year, 3 years, 5 years
- X-rays
- Time Frame: 6 weeks, 1 year, 3 years, 5 years
Safety Issue?: No
- Time Frame: 6 weeks, 1 year, 3 years, 5 years
Secondary Measures
- Incidence of revisions and removals
- Time Frame: Any time
Safety Issue?: Yes
- Time Frame: Any time
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis.
- Correction of functional deformity.
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques.
- Revision of previously failed femoral head resurfacing component
Exclusion Criteria:
Absolute contraindications include:
- infection,
- sepsis,
- osteomyelitis.
Relative contraindications include:
- uncooperative patient or patient with neurologic disorders who are incapable of following directions,
- osteoporosis,
- metabolic disorders which may impair bone formation,
- osteomalacia,
- distant foci of infections which may spread to the implant site,
- rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,
- vascular insufficiency, muscular atrophy, or neuromuscular disease.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Biomet Orthopedics, LLC
Overall Clinical Trial Officials and Contacts
Kenneth J Beres, MD Study Director Director, Clinical Research, Biomet Orthopedics, LLC
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00699088
Study ID Number: Biomet 13594-117
ClinicalTrials.gov Identifier: NCT00699088
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.